Abstract
The two clinical trials of irinotecan for the treatment of patients with advanced colorectal cancer described in today's Lancet clearly indicate some degree of activity of this topoisomerase I inhibitor in patients who had not responded to regimens containing fluorouracil. The prospective nature of the study, the randomisation, and careful statistical analysis contribute to the credibility of the major conclusion: irinotecan given as “second-line” chemotherapy can prolong survival and may improve quality of life.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call